Among the latest specialized treatment options available at the OSUCCC – James for patients with advanced liver cancer, such as cholangiocarcinoma or metastatic colorectal cancer to the liver, is hepatic artery infusion (HAI) pump therapy. An HAI pump is surgically placed, either by open or robotic-assisted approach with an insertion of connected catheter, into the gastroduodenal artery. This allows for highly selective liver-directed infusion of the chemotherapy agent, floxuridine, at 400 times the tolerated systemic dose. As a result, additional systemic toxicity is minimized, there’s greater potential for conversion to respectability and disease progression can be slowed. Since the inception of the HAI pump program in January 2021, our team has performed 18 HAI pump placements, which makes us one of the top volume centers in the country. In addition, Ohio State is a founding member of the U.S. HAI consortium to lead research and clinical trials.
